NAMS: PREVAIL’s interim analysis and upcoming RUBIN data position obicetrapib for a differentiated launch
Obicetrapib, a differentiated CETP inhibitor, is nearing key readouts from the PREVAIL cardiovascular outcomes trial and RUBIN diabetes study, with plans for launch in 12—18 months. PREVAIL’s interim analysis is set for Q4, focusing on robust LDL-lowering and additional benefits for diabetes and Al…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.